« Back
Home /
Pemetrexed (disodium hemipenta hydrate)

Pemetrexed (disodium hemipenta hydrate)

Item no.	HY-13781-10mM
Manufacturer	MedChem Express
CASRN	357166-30-4
Amount	10 mM/1 mL
Quantity options	100 mg 10 mM/1 mL 500 mg
Category	Oncology Neuroscience Neural Lineage Markers Targets for Rodent Neurosciences Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer Oligodendrocyte Markers
Type	Inhibitors
Specific against	other
Purity	99.78
Citations	[1]Shih C, et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997 Mar 15;57(6):1116-23.\|[2]Anraku M, et al. Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignantmesothelioma. J Immunol. 2010 Jul 15;185(2):956-66. J Mol Med (Berl). 2019 Aug;97(8):1183-1193. ACS Appl Mater Interfaces. 2025 Oct 8;17(40):55861-55875. Acta Pharmacol Sin. 2021 Jan;42(1):108-114. Adv Ther. 2024 Jul 18. Bioengineering (Basel). 2025 Oct 19;12(10):1121. Biol Methods Protoc. 2025 Feb 13;10(1):bpaf012. bioRxiv. 2024 June 12. bioRxiv. 2025 August 15. bioRxiv. 2025 January 21. bioRxiv. 2025 January 22. Br J Cancer. 2023 Aug;129(3):531-540. Cell Death Discov. 2022 Jul 5;8(1):307. Cell Rep Med. 2023 Feb 21;4(2):100911. Cell Rep Methods. 2023 Oct 23;3(10):100599. Commun Biol. 2022 Jun 23;5(1):619. Dev Cell. 2025 Sep 3:S1534-5807(25)00530-1. Eur J Med Res. 2025 Aug 4;30(1):704. Eur J Pharmacol. 2025 Apr 2:996:177584. Heliyon. 2024 Nov 8;10(22):e40299. Hum Cell. 2025 Apr 19;38(3):92. Int Immunopharmacol. 2023 Nov 3;125(Pt A):111158. Integr Cancer Ther. 2024 Jan-Dec:23:15347354241273962. J Clin Invest. 2021 Aug 2;131(15):e138022. J Control Release. 2023 Jan:353:490-506. J Pharm Anal. 2024 Apr 25:100984. Mol Cancer. 2024 Jan 10;23(1):12. Pharmacol Res Perspect. 2020 Apr;8(2):e00575. Pharmacol Res. 2024 May 9:204:107208. Res Sq. 2025 Sep 7. Research Square Print. September 27th, 2022. Sci Rep. 2025 Oct 16;15(1):36227. Theranostics. 2020 May 15;10(13):6048-6060. Beilstein J Org Chem. 2017 Oct 25:13:2252-2263. Clin Transl Oncol. 2022 Nov;24(11):2231-2240. Faculty of the Graduate School of Biomedical Sciences. The University of Texas Southwestern Medical Center. Oct 1. 2015. J Exp Clin Cancer Res. 2025 Oct 21;44(1):293. J Mol Med (Berl). 2019 Aug;97(8):1183-1193. Mol Cell. 2019 Dec 5;76(5):838-851.e5. Odontology. 2020 Apr;108(2):300-311.
Smiles	O=C(O[Na])CC[C@@H](C(O[Na])=O)NC(C1=CC=C(CCC2=CNC(N=C(N)N3)=C2C3=O)C=C1)=O.[2.5H2O]
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	LY231514 (disodium hemipenta hydrate)
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Category	Reference compound / Active compounds; API
Manufacturer - Targets	Antifolate; Apoptosis; Autophagy
Manufacturer - HS Code	H315, H319, H341, H360, H372
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	516.41
Product Description	Pemetrexed disodium hemipenta hydrate is a novel antifolate, the Ki values of the pentaglutamate of LY231514 are 1.3, 7.2, and 65 nM for inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), respectively.
Manufacturer - Research Area	Cancer
Solubility	DMSO : 2 mg/mL (ultrasonic)\|H2O : 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Apoptosis; Autophagy; Cell Cycle/DNA Damage
Clinical information	Launched
UNSPSC Code	12352005
Precautionary	H315, H319, H341, H360, H372

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.